Neglected Tropical Diseases Drugs and Vaccines Market Size, Share and Growth Outlook 2026: By Product Type (Drugs, Vaccines), By Disease, By Distribution Channel, Companies to 2034.
The global Neglected Tropical Diseases Drugs and Vaccines Market size is forecast to increase from $2.35 Billion in 2026 to $4.42 Billion in 2034 at a CAGR of 8.21% between 2026 and 2034.
The Neglected Tropical Diseases Drugs and Vaccines market report provides detailed analysis and outlook of Neglected Tropical Diseases Drugs and Vaccines segments including By Product Type (Drugs, Vaccines ), By Disease (Dengue and Chikungunya, Rabies, Trachoma, Leishmaniasis, Chagas Disease, Leprosy (Hansen’s Disease), Soil-Transmitted Helminthiases and Lymphatic Filariasis, Other Neglected Diseases ), By Distribution Channel (Public Sector and International Procurement Agencies, Hospital Pharmacies, Retail Pharmacies and Specialty Clinics, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Neglected Tropical Diseases (NTD) Drugs and Vaccines Industry Overview
Global Health Initiatives Are Accelerating NTD Drug and Vaccine Development
The neglected tropical diseases drugs and vaccines industry is gaining renewed momentum as international health organizations, pharmaceutical manufacturers, nonprofit research groups, and public-private partnerships intensify efforts to combat diseases that disproportionately affect populations in low- and middle-income countries. NTDs continue to represent a major public health burden, driving demand for improved prevention, diagnosis, and treatment strategies. Global programs increasingly focus on expanding access to medicines, strengthening vaccination coverage, and accelerating research into diseases that have historically received limited commercial investment. The World Health Organization’s Global Report on Neglected Tropical Diseases highlighted significant progress toward global elimination goals, including the donation of 19 different NTD medicines by 12 manufacturers and the delivery of 1.8 billion treatments. The prequalification of six new medicine formulations and a new dengue vaccine further demonstrates the industry's commitment to expanding therapeutic options for vulnerable populations.
Public-Private Partnerships Are Strengthening Research and Access Programs
Collaboration remains a defining characteristic of the NTD treatment landscape. Pharmaceutical companies, global health organizations, and funding agencies are increasingly coordinating efforts to improve access to medicines and vaccines while advancing clinical development programs. Partnerships involving Gavi, the Vaccine Alliance, continue to support large-scale rabies immunization initiatives in more than 50 high-burden countries as part of the global objective to eliminate human deaths from dog-mediated rabies. Simultaneously, WHO-led programs are encouraging integration of NTD management into national healthcare strategies, creating stronger frameworks for disease control, surveillance, and treatment delivery. These collaborative models are helping address longstanding challenges related to healthcare infrastructure, funding limitations, and equitable access to life-saving interventions in endemic regions.
Innovative Vaccine Platforms and Host-Directed Therapies Are Expanding Pipelines
The industry is increasingly focused on novel biologics, recombinant vaccines, and host-directed therapeutic approaches. Following WHO efforts to establish research priorities for NTDs, development activity has accelerated across diseases such as dengue and Chagas disease. IAVI strengthened vaccine innovation through its collaboration with The University of Texas Medical Branch to advance an rVSV-based vaccine candidate targeting Bundibugyo virus, supported by funding from the Coalition for Epidemic Preparedness Innovations. At the same time, the Drugs for Neglected Diseases initiative reported progress within its Dengue Alliance programs, validating sphingosine 1-phosphate receptor modulators as a promising strategy for reducing vascular leakage in dengue patients. Preclinical candidate profiling has generated data supporting future clinical studies. These developments illustrate a broader industry shift toward innovative vaccine technologies, targeted biologics, and mechanism-based therapies designed to address unmet medical needs across a diverse range of neglected tropical diseases.
Neglected Tropical Diseases Drugs and Vaccines Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Neglected Tropical Diseases Drugs and Vaccines market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Bayer AG, Sanofi S.A., Merck & Co., Inc, Novartis AG, Pfizer Inc., AstraZeneca plc, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited. The Neglected Tropical Diseases Drugs and Vaccines market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Neglected Tropical Diseases Drugs and Vaccines industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Neglected Tropical Diseases Drugs and Vaccines industry include- GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Bayer AG, Sanofi S.A., Merck & Co., Inc, Novartis AG, Pfizer Inc., AstraZeneca plc, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited. The Neglected Tropical Diseases Drugs and Vaccines market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Neglected Tropical Diseases Drugs and Vaccines Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Neglected Tropical Diseases Drugs and Vaccines market remains one of the strongest-performing segments in the country.
The US Neglected Tropical Diseases Drugs and Vaccines Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Neglected Tropical Diseases Drugs and Vaccines market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Neglected Tropical Diseases Drugs and Vaccines industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Neglected Tropical Diseases Drugs and Vaccines markets
Canada's strong Neglected Tropical Diseases Drugs and Vaccines sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Neglected Tropical Diseases Drugs and Vaccines market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Neglected Tropical Diseases Drugs and Vaccines Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Neglected Tropical Diseases Drugs and Vaccines market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Neglected Tropical Diseases Drugs and Vaccines population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Neglected Tropical Diseases Drugs and Vaccines industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Neglected Tropical Diseases Drugs and Vaccines market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Neglected Tropical Diseases Drugs and Vaccines sales through 2034
France Neglected Tropical Diseases Drugs and Vaccines companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Neglected Tropical Diseases Drugs and Vaccines Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Neglected Tropical Diseases Drugs and Vaccines distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Neglected Tropical Diseases Drugs and Vaccines Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Neglected Tropical Diseases Drugs and Vaccines market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Neglected Tropical Diseases Drugs and Vaccines industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Neglected Tropical Diseases Drugs and Vaccines industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Neglected Tropical Diseases Drugs and Vaccines Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Neglected Tropical Diseases Drugs and Vaccines market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Neglected Tropical Diseases Drugs and Vaccines market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Neglected Tropical Diseases Drugs and Vaccines Market Segmentation
By Product Type
Drugs
Vaccines
By Disease
Dengue and Chikungunya
Rabies
Trachoma
Leishmaniasis
Chagas Disease
Leprosy (Hansen’s Disease)
Soil-Transmitted Helminthiases and Lymphatic Filariasis
Other Neglected Diseases
By Distribution Channel
Public Sector and International Procurement Agencies
Hospital Pharmacies
Retail Pharmacies and Specialty Clinics
Others
Leading Companies in Neglected Tropical Diseases Drugs and Vaccines Industry (2026)
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Bayer AG
Sanofi S.A.
Merck & Co., Inc
Novartis AG
Pfizer Inc.
AstraZeneca plc
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
Countries Included
The Neglected Tropical Diseases Drugs and Vaccines market report provides detailed analysis and outlook of Neglected Tropical Diseases Drugs and Vaccines segments including By Product Type (Drugs, Vaccines ), By Disease (Dengue and Chikungunya, Rabies, Trachoma, Leishmaniasis, Chagas Disease, Leprosy (Hansen’s Disease), Soil-Transmitted Helminthiases and Lymphatic Filariasis, Other Neglected Diseases ), By Distribution Channel (Public Sector and International Procurement Agencies, Hospital Pharmacies, Retail Pharmacies and Specialty Clinics, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Neglected Tropical Diseases (NTD) Drugs and Vaccines Industry Overview
Global Health Initiatives Are Accelerating NTD Drug and Vaccine Development
The neglected tropical diseases drugs and vaccines industry is gaining renewed momentum as international health organizations, pharmaceutical manufacturers, nonprofit research groups, and public-private partnerships intensify efforts to combat diseases that disproportionately affect populations in low- and middle-income countries. NTDs continue to represent a major public health burden, driving demand for improved prevention, diagnosis, and treatment strategies. Global programs increasingly focus on expanding access to medicines, strengthening vaccination coverage, and accelerating research into diseases that have historically received limited commercial investment. The World Health Organization’s Global Report on Neglected Tropical Diseases highlighted significant progress toward global elimination goals, including the donation of 19 different NTD medicines by 12 manufacturers and the delivery of 1.8 billion treatments. The prequalification of six new medicine formulations and a new dengue vaccine further demonstrates the industry's commitment to expanding therapeutic options for vulnerable populations.
Public-Private Partnerships Are Strengthening Research and Access Programs
Collaboration remains a defining characteristic of the NTD treatment landscape. Pharmaceutical companies, global health organizations, and funding agencies are increasingly coordinating efforts to improve access to medicines and vaccines while advancing clinical development programs. Partnerships involving Gavi, the Vaccine Alliance, continue to support large-scale rabies immunization initiatives in more than 50 high-burden countries as part of the global objective to eliminate human deaths from dog-mediated rabies. Simultaneously, WHO-led programs are encouraging integration of NTD management into national healthcare strategies, creating stronger frameworks for disease control, surveillance, and treatment delivery. These collaborative models are helping address longstanding challenges related to healthcare infrastructure, funding limitations, and equitable access to life-saving interventions in endemic regions.
Innovative Vaccine Platforms and Host-Directed Therapies Are Expanding Pipelines
The industry is increasingly focused on novel biologics, recombinant vaccines, and host-directed therapeutic approaches. Following WHO efforts to establish research priorities for NTDs, development activity has accelerated across diseases such as dengue and Chagas disease. IAVI strengthened vaccine innovation through its collaboration with The University of Texas Medical Branch to advance an rVSV-based vaccine candidate targeting Bundibugyo virus, supported by funding from the Coalition for Epidemic Preparedness Innovations. At the same time, the Drugs for Neglected Diseases initiative reported progress within its Dengue Alliance programs, validating sphingosine 1-phosphate receptor modulators as a promising strategy for reducing vascular leakage in dengue patients. Preclinical candidate profiling has generated data supporting future clinical studies. These developments illustrate a broader industry shift toward innovative vaccine technologies, targeted biologics, and mechanism-based therapies designed to address unmet medical needs across a diverse range of neglected tropical diseases.
Neglected Tropical Diseases Drugs and Vaccines Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Neglected Tropical Diseases Drugs and Vaccines market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Bayer AG, Sanofi S.A., Merck & Co., Inc, Novartis AG, Pfizer Inc., AstraZeneca plc, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited. The Neglected Tropical Diseases Drugs and Vaccines market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Neglected Tropical Diseases Drugs and Vaccines industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Neglected Tropical Diseases Drugs and Vaccines Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Neglected Tropical Diseases Drugs and Vaccines companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Neglected Tropical Diseases Drugs and Vaccines markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Neglected Tropical Diseases Drugs and Vaccines industry include- GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Bayer AG, Sanofi S.A., Merck & Co., Inc, Novartis AG, Pfizer Inc., AstraZeneca plc, Eisai Co., Ltd., Takeda Pharmaceutical Company Limited. The Neglected Tropical Diseases Drugs and Vaccines market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Neglected Tropical Diseases Drugs and Vaccines Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Neglected Tropical Diseases Drugs and Vaccines market remains one of the strongest-performing segments in the country.
The US Neglected Tropical Diseases Drugs and Vaccines Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Neglected Tropical Diseases Drugs and Vaccines market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Neglected Tropical Diseases Drugs and Vaccines industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Neglected Tropical Diseases Drugs and Vaccines markets
Canada's strong Neglected Tropical Diseases Drugs and Vaccines sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Neglected Tropical Diseases Drugs and Vaccines market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Neglected Tropical Diseases Drugs and Vaccines Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Neglected Tropical Diseases Drugs and Vaccines market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Neglected Tropical Diseases Drugs and Vaccines population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Neglected Tropical Diseases Drugs and Vaccines industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Neglected Tropical Diseases Drugs and Vaccines market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Neglected Tropical Diseases Drugs and Vaccines sales through 2034
France Neglected Tropical Diseases Drugs and Vaccines companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Neglected Tropical Diseases Drugs and Vaccines Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Neglected Tropical Diseases Drugs and Vaccines distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Neglected Tropical Diseases Drugs and Vaccines Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Neglected Tropical Diseases Drugs and Vaccines market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Neglected Tropical Diseases Drugs and Vaccines industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Neglected Tropical Diseases Drugs and Vaccines industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Neglected Tropical Diseases Drugs and Vaccines Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Neglected Tropical Diseases Drugs and Vaccines market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Neglected Tropical Diseases Drugs and Vaccines market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Neglected Tropical Diseases Drugs and Vaccines Market Segmentation
By Product Type
Drugs
Vaccines
By Disease
Dengue and Chikungunya
Rabies
Trachoma
Leishmaniasis
Chagas Disease
Leprosy (Hansen’s Disease)
Soil-Transmitted Helminthiases and Lymphatic Filariasis
Other Neglected Diseases
By Distribution Channel
Public Sector and International Procurement Agencies
Hospital Pharmacies
Retail Pharmacies and Specialty Clinics
Others
Leading Companies in Neglected Tropical Diseases Drugs and Vaccines Industry (2026)
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Bayer AG
Sanofi S.A.
Merck & Co., Inc
Novartis AG
Pfizer Inc.
AstraZeneca plc
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Neglected Tropical Diseases Drugs and Vaccines Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Neglected Tropical Diseases Drugs and Vaccines Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Neglected Tropical Diseases Drugs and Vaccines Markets in 2026
3.2. Global Historic and Forecast Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Neglected Tropical Diseases Drugs and Vaccines Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Neglected Tropical Diseases Drugs and Vaccines Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Neglected Tropical Diseases Drugs and Vaccines Value Chain
CHAPTER 4- NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Neglected Tropical Diseases Drugs and Vaccines Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Drugs
Vaccines
By Disease
Dengue and Chikungunya
Rabies
Trachoma
Leishmaniasis
Chagas Disease
Leprosy (Hansen’s Disease)
Soil-Transmitted Helminthiases and Lymphatic Filariasis
Other Neglected Diseases
By Distribution Channel
Public Sector and International Procurement Agencies
Hospital Pharmacies
Retail Pharmacies and Specialty Clinics
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
7.5. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
7.6. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
7.7. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Neglected Tropical Diseases Drugs and Vaccines Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Neglected Tropical Diseases Drugs and Vaccines Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 8- EUROPE NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
8.5. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
8.6. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
8.7. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Neglected Tropical Diseases Drugs and Vaccines Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Neglected Tropical Diseases Drugs and Vaccines Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Neglected Tropical Diseases Drugs and Vaccines Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Neglected Tropical Diseases Drugs and Vaccines Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Neglected Tropical Diseases Drugs and Vaccines Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 9- ASIA PACIFIC NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
9.6. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
9.7. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Neglected Tropical Diseases Drugs and Vaccines Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Neglected Tropical Diseases Drugs and Vaccines Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Neglected Tropical Diseases Drugs and Vaccines Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Neglected Tropical Diseases Drugs and Vaccines Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Neglected Tropical Diseases Drugs and Vaccines Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
10.5. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
10.6. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
10.7. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Neglected Tropical Diseases Drugs and Vaccines Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Neglected Tropical Diseases Drugs and Vaccines Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
11.6. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
11.7. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Neglected Tropical Diseases Drugs and Vaccines Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Neglected Tropical Diseases Drugs and Vaccines Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Neglected Tropical Diseases Drugs and Vaccines Industry
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Bayer AG
Sanofi S.A.
Merck & Co., Inc
Novartis AG
Pfizer Inc.
AstraZeneca plc
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Neglected Tropical Diseases Drugs and Vaccines Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Neglected Tropical Diseases Drugs and Vaccines Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Neglected Tropical Diseases Drugs and Vaccines Markets in 2026
3.2. Global Historic and Forecast Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Neglected Tropical Diseases Drugs and Vaccines Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Neglected Tropical Diseases Drugs and Vaccines Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Neglected Tropical Diseases Drugs and Vaccines Value Chain
CHAPTER 4- NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Neglected Tropical Diseases Drugs and Vaccines Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Drugs
Vaccines
By Disease
Dengue and Chikungunya
Rabies
Trachoma
Leishmaniasis
Chagas Disease
Leprosy (Hansen’s Disease)
Soil-Transmitted Helminthiases and Lymphatic Filariasis
Other Neglected Diseases
By Distribution Channel
Public Sector and International Procurement Agencies
Hospital Pharmacies
Retail Pharmacies and Specialty Clinics
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
7.5. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
7.6. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
7.7. North America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Neglected Tropical Diseases Drugs and Vaccines Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Neglected Tropical Diseases Drugs and Vaccines Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 8- EUROPE NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
8.5. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
8.6. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
8.7. Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Neglected Tropical Diseases Drugs and Vaccines Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Neglected Tropical Diseases Drugs and Vaccines Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Neglected Tropical Diseases Drugs and Vaccines Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Neglected Tropical Diseases Drugs and Vaccines Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Neglected Tropical Diseases Drugs and Vaccines Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 9- ASIA PACIFIC NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
9.6. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
9.7. Asia Pacific Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Neglected Tropical Diseases Drugs and Vaccines Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Neglected Tropical Diseases Drugs and Vaccines Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Neglected Tropical Diseases Drugs and Vaccines Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Neglected Tropical Diseases Drugs and Vaccines Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Neglected Tropical Diseases Drugs and Vaccines Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
10.5. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
10.6. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
10.7. South and Central America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Neglected Tropical Diseases Drugs and Vaccines Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Neglected Tropical Diseases Drugs and Vaccines Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NEGLECTED TROPICAL DISEASES DRUGS AND VACCINES MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Type
11.6. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Application
11.7. Middle East and Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Neglected Tropical Diseases Drugs and Vaccines Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Neglected Tropical Diseases Drugs and Vaccines Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Neglected Tropical Diseases Drugs and Vaccines Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Neglected Tropical Diseases Drugs and Vaccines Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Neglected Tropical Diseases Drugs and Vaccines Industry
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Bayer AG
Sanofi S.A.
Merck & Co., Inc
Novartis AG
Pfizer Inc.
AstraZeneca plc
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
